Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
16
03
2023
accepted:
03
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
epublish
Résumé
Testicular germ cell tumours (TGCT), which comprise seminoma and non-seminoma subtypes, are the most common cancers in young men. In this study, we present a comprehensive whole genome sequencing analysis of adult TGCTs. Leveraging samples from participants recruited via the UK National Health Service and data from the Genomics England 100,000 Genomes Project, our results provide an extended description of genomic elements underlying TGCT pathogenesis. This catalogue offers a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genome features, including mutational signatures and analysis of extrachromosomal DNA amplification. This study establishes correlations between genomic alterations and histological diversification, revealing divergent evolutionary trajectories among TGCT subtypes. By reconstructing the chronological order of driver events, we identify a subgroup of adult TGCTs undergoing relatively late whole genome duplication. Additionally, we present evidence that human leukocyte antigen loss is a more prevalent mechanism of immune disruption in seminomas. Collectively, our findings provide valuable insights into the developmental and immune modulatory processes implicated in TGCT pathogenesis and progression.
Identifiants
pubmed: 39461959
doi: 10.1038/s41467-024-53193-6
pii: 10.1038/s41467-024-53193-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9247Informations de copyright
© 2024. The Author(s).
Références
Cancer Research UK. Testicular Cancer Statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicular-cancer (2022).
Moch, H. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours. Eur. Urol. 82, 458–468 (2022).
pubmed: 35853783
doi: 10.1016/j.eururo.2022.06.016
Oosterhuis, J. W. & Looijenga, L. H. J. Human germ cell tumours from a developmental perspective. Nat. Rev. Cancer 19, 522–537 (2019).
pubmed: 31413324
doi: 10.1038/s41568-019-0178-9
Litchfield, K. et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat. Commun. 6, 5973 (2015).
pubmed: 25609015
pmcid: 4338546
doi: 10.1038/ncomms6973
Shen, H. et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 23, 3392–3406 (2018).
pubmed: 29898407
pmcid: 6075738
doi: 10.1016/j.celrep.2018.05.039
Cheng, M. L. et al. Germ cell tumor molecular heterogeneity revealed through analysis of primary and metastasis pairs. JCO Precis Oncol. 4, 1307–1320 (2020).
doi: 10.1200/PO.20.00166
Taylor-Weiner, A. et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature 540, 114–118 (2016).
pubmed: 27905446
pmcid: 5553306
doi: 10.1038/nature20596
Loveday, C. et al. Genomic landscape of platinum resistant and sensitive testicular cancers. Nat. Commun. 11, 1–12 (2020).
doi: 10.1038/s41467-020-15768-x
Xu, L. et al. Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence. Nat. Commun. 14, 2636 (2023).
pubmed: 37149691
pmcid: 10164134
doi: 10.1038/s41467-023-38378-9
Dorssers, L. C. J. et al. Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development. Br. J. Cancer 120, 444–452 (2019).
pubmed: 30739914
pmcid: 6461884
doi: 10.1038/s41416-019-0381-1
Oliver, T. R. W. et al. Clonal diversification and histogenesis of malignant germ cell tumours. Nat. Commun. 13, 4272 (2022).
pubmed: 35953478
pmcid: 9372159
doi: 10.1038/s41467-022-31375-4
Turnbull, C. Introducing whole-genome sequencing into routine cancer care: the genomics england 100 000 genomes project. Ann. Oncol. 29, 784–787 (2018).
pubmed: 29462260
doi: 10.1093/annonc/mdy054
Turro, E. et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature 583, 96–102 (2020).
pubmed: 32581362
pmcid: 7610553
doi: 10.1038/s41586-020-2434-2
Willmore-Payne, C., Holden, J. A., Chadwick, B. E. & Layfield, L. J. Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. Mod. Pathol. 19, 1164–1169 (2006).
pubmed: 16741525
doi: 10.1038/modpathol.3800623
Wang, L. et al. Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511, 241–245 (2014).
pubmed: 24896186
pmcid: 4532372
doi: 10.1038/nature13296
Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. OncodriveFML: A general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 17, 128 (2016).
pubmed: 27311963
pmcid: 4910259
doi: 10.1186/s13059-016-0994-0
Arnedo-Pac, C., Mularoni, L., Muiños, F., Gonzalez-Perez, A. & Lopez-Bigas, N. OncodriveCLUSTL: A sequence-based clustering method to identify cancer drivers. Bioinformatics 35, 4788–4790 (2019).
pubmed: 31228182
pmcid: 6853674
doi: 10.1093/bioinformatics/btz501
Zhu, H. et al. Candidate cancer driver mutations in distal regulatory elements and long-range chromatin interaction networks. Mol. Cell 77, 1307–1321.e10 (2020).
pubmed: 31954095
doi: 10.1016/j.molcel.2019.12.027
Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563–575.e11 (2022).
pubmed: 35120664
pmcid: 9147702
doi: 10.1016/j.cell.2022.01.003
Brabrand, S. et al. Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages. Neoplasia 17, 167–174 (2015).
pubmed: 25748235
pmcid: 4351294
doi: 10.1016/j.neo.2014.12.005
Venditti, M., Arcaniolo, D., De Sio, M. & Minucci, S. First evidence of the expression and localization of prothymosin α in human testis and its involvement in testicular cancers. Biomolecules 12, 1210 (2022).
pubmed: 36139050
pmcid: 9496091
doi: 10.3390/biom12091210
Chakravarty, D. et al. OncoKB: A precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).
Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
pubmed: 22608083
pmcid: 3428864
doi: 10.1016/j.cell.2012.04.023
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
pubmed: 21527027
pmcid: 3218867
doi: 10.1186/gb-2011-12-4-r41
Pluta, J. et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat. Commun. 12, 1–13 (2021).
doi: 10.1038/s41467-021-24334-y
Nazeer, T. et al. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases. Oncol. Rep. 5, 1425–1429 (1998).
pubmed: 9769381
Yuasa, T. et al. Detection of alpha-fetoprotein mRNA in seminoma. J. Androl. 20, 336–340 (1999).
pubmed: 10386812
doi: 10.1002/j.1939-4640.1999.tb02526.x
Looijenga, L. H. J. et al. Role of gain of 12p in germ cell tumour development. APMIS 111, 161–171 (2003). discussion 172–3.
pubmed: 12752258
doi: 10.1034/j.1600-0463.2003.11101201.x
Geurts van Kessel, A. et al. Chromosome 12q heterozygosity is retained in i(12p)-positive testicular germ cell tumor cells. Cancer Genet. Cytogenet. 40, 129–134 (1989).
pubmed: 2569358
doi: 10.1016/0165-4608(89)90154-4
Glodzik, D. et al. A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. Nat. Genet. 49, 341–348 (2017).
pubmed: 28112740
pmcid: 5988034
doi: 10.1038/ng.3771
Berry, L. W., Westlund, B. & Schedl, T. Germ-line tumor formation caused by activation of glp-1, a Caenorhabditis elegans member of the Notch family of receptors. Development 124, 925–936 (1997).
pubmed: 9043073
doi: 10.1242/dev.124.4.925
Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891–897 (2020).
pubmed: 32807987
pmcid: 7484012
doi: 10.1038/s41588-020-0678-2
Deshpande, V. et al. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat. Commun. 10, 392 (2019).
pubmed: 30674876
pmcid: 6344493
doi: 10.1038/s41467-018-08200-y
Zakov, S., Kinsella, M. & Bafna, V. An algorithmic approach for breakage-fusion-bridge detection in tumor genomes. Proc. Natl Acad. Sci. USA. 110, 5546–5551 (2013).
pubmed: 23503850
pmcid: 3619374
doi: 10.1073/pnas.1220977110
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018
pmcid: 7054213
doi: 10.1038/s41586-020-1943-3
Coorens, T. H. H. et al. Inherent mosaicism and extensive mutation of human placentas. Nature 592, 80–85 (2021).
pubmed: 33692543
pmcid: 7611644
doi: 10.1038/s41586-021-03345-1
Inman, G. J. et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat. Commun. 9, 3667 (2018).
pubmed: 30202019
pmcid: 6131170
doi: 10.1038/s41467-018-06027-1
Gunnarsson, R. et al. Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia. Leukemia 36, 1681–1684 (2022).
pubmed: 35365774
pmcid: 9162923
doi: 10.1038/s41375-022-01552-x
Steele, C. D. et al. Signatures of copy number alterations in human cancer. Nature 606, 984–991 (2022).
pubmed: 35705804
pmcid: 9242861
doi: 10.1038/s41586-022-04738-6
Degasperi, A. et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat. Cancer 1, 249–263 (2020).
pubmed: 32118208
pmcid: 7048622
doi: 10.1038/s43018-020-0027-5
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
pubmed: 32025013
pmcid: 7054212
doi: 10.1038/s41586-019-1907-7
Sohni, A. et al. The neonatal and adult human testis defined at the single-cell level. Cell Rep. 26, 1501–1517.e4 (2019).
pubmed: 30726734
pmcid: 6402825
doi: 10.1016/j.celrep.2019.01.045
Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat. Genet. 48, 126–133 (2016).
pubmed: 26656846
doi: 10.1038/ng.3469
Jakobsdottir, G. M., Dentro, S. C., Bristow, R. G. & Wedge, D. C. AmplificationTimeR: an R package for timing sequential amplification events. Bioinformatics 40, btae281 (2024).
Bolli, N. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun. 5, 2997 (2014).
pubmed: 24429703
doi: 10.1038/ncomms3997
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271.e11 (2017).
pubmed: 29107330
pmcid: 5720478
doi: 10.1016/j.cell.2017.10.001
Newton, S. C., Blaschuk, O. W. & Millette, C. F. N-cadherin mediates Sertoli cell-spermatogenic cell adhesion. Dev. Dyn. 197, 1–13 (1993).
pubmed: 8400407
doi: 10.1002/aja.1001970102
Giannoulatou, E. et al. Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. PLoS One 12, e0178169 (2017).
pubmed: 28542371
pmcid: 5439955
doi: 10.1371/journal.pone.0178169
Moore, L. et al. The mutational landscape of human somatic and germline cells. Nature 597, 381–386 (2021).
pubmed: 34433962
doi: 10.1038/s41586-021-03822-7
Strohsnitter, W. C. et al. Cancer risk in men exposed in Utero to Diethylstilbestrol. J. Natl Cancer Inst. 93, 545–551 (2001).
pubmed: 11287449
doi: 10.1093/jnci/93.7.545
Shetty, G., Comish, P. B., Weng, C. C. Y., Matin, A. & Meistrich, M. L. Fetal radiation exposure induces testicular cancer in genetically susceptible mice. PLoS One 7, e32064 (2012).
pubmed: 22348147
pmcid: 3278464
doi: 10.1371/journal.pone.0032064
Funt, S. A. et al. Impact of teratoma on the cumulative incidence of disease-related death in patients with advanced germ cell tumors. J. Clin. Oncol. 37, 2329–2337 (2019).
pubmed: 31233353
pmcid: 7001787
doi: 10.1200/JCO.18.01608
Brandsma, A. M. et al. Mutation signatures of pediatric acute myeloid leukemia and normal blood progenitors associated with differential patient outcomes. Blood Cancer Discov. 2, 484–499 (2021).
pubmed: 34642666
pmcid: 7611805
doi: 10.1158/2643-3230.BCD-21-0010
Linder, N. et al. Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. J. Clin. Pathol. 72, 157–164 (2019).
pubmed: 30518631
doi: 10.1136/jclinpath-2018-205328
Montesion, M. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282–292 (2021).
pubmed: 33127846
doi: 10.1158/2159-8290.CD-20-0672
Oosterhuis, J. W. & Looijenga, L. H. J. in Encyclopedia of Cancer 3rd ed. (eds. Boffetta, P. & Hainaut, P.) 121–153 (Elsevier Inc., Amsterdam, The Netherlands, 2019).
Tian, Q., Frierson, H. F. Jr, Krystal, G. W. & Moskaluk, C. A. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 154, 1643–1647 (1999).
pubmed: 10362788
pmcid: 1876773
doi: 10.1016/S0002-9440(10)65419-3
Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).
pubmed: 30013048
doi: 10.1038/s41592-018-0051-x
Sosinsky, A. et al. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 genomes cancer programme. Nat. Med. 30, 279–289 (2024).
pubmed: 38200255
pmcid: 10803271
doi: 10.1038/s41591-023-02682-0
Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
pubmed: 30371878
doi: 10.1093/nar/gky1015
Benson, G. Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acids Res. 27, 573–580 (1999).
pubmed: 9862982
pmcid: 148217
doi: 10.1093/nar/27.2.573
Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980–D985 (2014).
pubmed: 24234437
doi: 10.1093/nar/gkt1113
Martínez-Jiménez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555–572 (2020).
pubmed: 32778778
doi: 10.1038/s41568-020-0290-x
Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239–2254.e39 (2021).
pubmed: 33831375
pmcid: 8054914
doi: 10.1016/j.cell.2021.03.009
Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333–i339 (2012).
pubmed: 22962449
pmcid: 3436805
doi: 10.1093/bioinformatics/bts378
Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for structural variant discovery. Genome Biol. 15, R84 (2014).
pubmed: 24970577
pmcid: 4197822
doi: 10.1186/gb-2014-15-6-r84
Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220–1222 (2016).
pubmed: 26647377
doi: 10.1093/bioinformatics/btv710
Li, Y. et al. Patterns of somatic structural variation in human cancer genomes. Nature 578, 112–121 (2020).
pubmed: 32025012
pmcid: 7025897
doi: 10.1038/s41586-019-1913-9
Islam, A. et al. Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. bioRxiv https://doi.org/10.1101/2020.12.13.422570 (2021).
Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152–1158 (2015).
pubmed: 26372948
pmcid: 4747795
doi: 10.1038/nbt.3344
Caulfield, M. et al. National Genomic Research Library [Dataset]. figshare https://doi.org/10.6084/m9.figshare.4530893.v7 (2017).